SCHEMBL7688541

SCHEMBL7688541

CC(OS(C)(=O)=O)c1ccccc1

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.42
HCAR2 Q8TDS4 1/20 0.42
KMT2A Q03164 2/20 0.39
CYP3A4 P08684 1/20 0.39
KDM4E B2RXH2 1/20 0.39
GMNN O75496 1/20 0.39
LMNA P02545 1/20 0.39
POLB P06746 1/20 0.39
MAPT P10636 1/20 0.39
HPGD P15428 1/20 0.39
PMP22 Q01453 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
FFAR1 O14842 1/20 0.37
SRC P12931 1/20 0.36
ADRA2A P08913 1/20 0.36
ADRA2B P18089 1/20 0.36
ADRA2C P18825 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8241125 1.00 ALDH1A1 (0.42) ALDH1A1HCAR2KMT2ACYP3A4KDM4E
SCHEMBL8115614 1.00 ALDH1A1 (0.42) ALDH1A1HCAR2KMT2ACYP3A4KDM4E
Nitrous Acid SCHEMBL7868432 0.88 HCAR2 (0.38) ALDH1A1HCAR2KMT2ACYP3A4KDM4E
SCHEMBL5892165 0.81 CA1 (0.44) HCAR2KMT2A
SCHEMBL17789740 0.81 ALDH1A1 (0.41) ALDH1A1KMT2AMAPTTDP1
SCHEMBL776266 0.81 KMT2A (0.46) ALDH1A1HCAR2KMT2AKDM4EGMNN
SCHEMBL6670749 0.80 LMNA (0.41) ALDH1A1KMT2ACYP3A4KDM4ELMNA
SCHEMBL2476595 0.79 HCAR2 (0.40) ALDH1A1HCAR2KMT2AKDM4EGMNN
SCHEMBL24335753 0.79 CYP19A1 (0.40) ALDH1A1CYP3A4POLBMAPTHPGD
SCHEMBL8551002 0.79 ADRB2 (0.43) ALDH1A1CYP3A4TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250230170-A1 Process for the Steroselective Preparation of Chiral 2-[(Hetero)Arylalkylsulfanyl]Pyrimidines and Products Obtainable Therefrom KANCERA AB (SE) 2025-07-17 US disclosed
US-12264165-B2 Process for the stereoselective preparation of chiral 2-[(hetero) arylalkylsulfanyl]pyrimidines and products obtainable therefrom KANCERA AB (SE) 2025-04-01 US disclosed
US-20230322807-A1 Process for the Steroselective Preparation of Chiral 2-[(Hetero)Arylalkylsulfanyl]Pyrimidines and Products Obtainable Therefrom KANCERA AB (SE) 2023-10-12 US disclosed
US-11691988-B2 Process for the stereoselective preparation of chiral 2-[(hetero)arylalkylsulfanyl]pyrimidines and products obtainable therefrom KANCERA AB (SE) 2023-07-04 US disclosed
US-20230068240-A1 A Process for the Steroselective Preparation of Chiral 2-[(Hetero)Arylalkylsulfanyl]Pyrimidines and Products Obtainable Therefrom KANCERA AB (SE) 2023-03-02 US disclosed
US-11542281-B2 Process for the steroselective preparation of chiral 2- [(hetero)arylalkylsulfanyl] pyrimidines and products obtainable therefrom KANCERA AB (SE) 2023-01-03 US disclosed
US-11450445-B2 Electroconductive film and method for manufacturing electroconductive pattern TOKYO UNIVERSITY OF SCIENCE FOUNDATION (JP) 2022-09-20 US disclosed
US-20210188873-A1 A Process for the Steroselective Preparation of Chiral 2-[(Hetero)Arylalkylsulfanyl]Pyrimidines and Products Obtainable Therefrom KANCERA AB (SE) 2021-06-24 US disclosed
CN-112218853-A Process for the stereoselective preparation of chiral 2- [ (hetero) aralkylthio ] pyrimidines and products obtainable therefrom 坎塞拉有限公司 2021-01-12 CN disclosed
US-20200303086-A1 ELECTROCONDUCTIVE FILM AND METHOD FOR MANUFACTURING ELECTROCONDUCTIVE PATTERN TOKYO UNIVERSITY OF SCIENCE FOUNDATION (JP) 2020-09-24 US disclosed
US-9713619-B2 Compounds, compositions and methods useful for cholesterol mobilization CERENIS THERAPEUTICS HOLDING SA (FR) 2017-07-25 US disclosed
WO-2016092478-A1 PROCESS FOR PREPARATION OF LULICONAZOLE GLENMARK PHARMACEUTICALS LIMITED (IN) 2016-06-16 WO disclosed
US-8912330-B2 Azaindole derivatives as kinase inhibitors ARIAD PHARMACEUTICALS, INC. (US) 2014-12-16 US disclosed
US-20110294806-A1 AZAINDOLE DERIVATIVES AS KINASE INHIBITORS ARIAD PHARMACEUTICALS, INC. (US) 2011-12-01 US disclosed
US-6346540-B1 SUBSTANCE P ANTAGONISTS FOR TREATING CENTRAL NERVOUS SYSTEM, PSYCHOLOGICAL AND BRAIN DISORDERS JANSSEN PHARMACEUTICA N.V. (BE) 2002-02-12 US disclosed
EP-0855999-B1 1-(1,2-DISUBSTITUTED PIPERIDINYL)-4-SUBSTITUTED PIPERIDINE DERIVATIVES AS TACHYKININ RECEPTOR ANTAGONISTS JANSSEN PHARMACEUTICA NV (BE) 2001-10-04 EP disclosed
US-6169097-B1 1-(1,2-Disubstituted piperidinyl)-4-substituted piperidine derivatives JANSSEN PHARMACEUTICA N.V. (BE) 2001-01-02 US disclosed
EP-0855999-A1 1-(1,2-DISUBSTITUTED PIPERIDINYL)-4-SUBSTITUTED PIPERIDINE DERIVATIVES AS TACHYKININ RECEPTOR ANTAGONISTS JANSSEN PHARMACEUTICA N.V. (BE) 1998-08-05 EP disclosed
WO-1997024324-A1 1-(1,2-DISUBSTITUTED PIPERIDINYL)-4-SUBSTITUTED PIPERIDINE DERIVATIVES AS TACHYKININ RECEPTOR ANTAGONISTS JANSSEN PHARMACEUTICA N.V. (BE) 1997-07-10 WO disclosed
US-5446011-A Imagewise coloring when heating; mixture of n-substituted indole, aromatic polyhydroxy compound, carbonyl compound and an acid RICOH COMPANY, LTD. (JP) 1995-08-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230322807-A1 Process for the Steroselective Preparation of Chiral 2-[(Hetero)Arylalkylsulfanyl]Pyrimidines and Products Obtainable Therefrom CYP2S1, CYP2B6, CYP2F1 ALDH1A1 333/4885HCAR2 1592/4885KMT2A 4025/4885
US-12264165-B2 Process for the stereoselective preparation of chiral 2-[(hetero) arylalkylsulfanyl]pyrimidines and products obtainable therefrom CYP2B6, CYP2S1, CYP2D6 ALDH1A1 306/4885HCAR2 1026/4885KMT2A 4060/4885
US-11542281-B2 Process for the steroselective preparation of chiral 2- [(hetero)arylalkylsulfanyl] pyrimidines and products obtainable therefrom CYP2S1, CYP2B6, CYP2F1 ALDH1A1 333/4885HCAR2 1592/4885KMT2A 4025/4885
US-20210188873-A1 A Process for the Steroselective Preparation of Chiral 2-[(Hetero)Arylalkylsulfanyl]Pyrimidines and Products Obtainable Therefrom CYP2S1, CYP2B6, TYMS ALDH1A1 272/4885HCAR2 1661/4885KMT2A 4093/4885
US-20230068240-A1 A Process for the Steroselective Preparation of Chiral 2-[(Hetero)Arylalkylsulfanyl]Pyrimidines and Products Obtainable Therefrom CYP2S1, CYP2B6, TYMS ALDH1A1 272/4885HCAR2 1661/4885KMT2A 4093/4885
US-20110294806-A1 AZAINDOLE DERIVATIVES AS KINASE INHIBITORS ABL1, CDKN1A, MAP3K13 ALDH1A1 2111/4885HCAR2 2658/4885KMT2A 408/4885
US-20250230170-A1 Process for the Steroselective Preparation of Chiral 2-[(Hetero)Arylalkylsulfanyl]Pyrimidines and Products Obtainable Therefrom CYP2S1, CYP2B6, CYP2F1 ALDH1A1 333/4885HCAR2 1592/4885KMT2A 4025/4885
US-11691988-B2 Process for the stereoselective preparation of chiral 2-[(hetero)arylalkylsulfanyl]pyrimidines and products obtainable therefrom CYP2B6, CYP2S1, CYP2D6 ALDH1A1 306/4885HCAR2 1026/4885KMT2A 4060/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.